On May 17, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx (Press release, Ambrx, MAY 17, 2022, View Source [SID1234614758]). Dr. Lu is a distinguished clinical professor of medicine who has more than 18 years of experience in leading clinical trials and breast cancer drug development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am delighted to welcome Janice Lu to the Ambrx team and look forward to leveraging her insight in breast oncology to continue to progress ARX788 through the clinic," said Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx. "Janice has been a valuable asset as a principal investigator for multiple Ambrx trials, including the Phase 1 ACE-Pan Tumor-01 and Phase 2 ACE-Breast-03 clinical trials, and is the ideal candidate to take the role of CMO at our company. I look forward to leaning on Janice’s expertise to further our current research and development efforts in the treatment of oncology."

"I am impressed with the encouraging data from the ongoing clinical trials of ARX788 and Ambrx’s engineered precision biologics technology platform," said Dr. Lu. "I am excited to begin working with Ambrx in this new capacity, assisting with the ongoing development of their clinical development pipeline and overseeing the clinical operations. I believe our consorted efforts will potentially provide therapeutic treatment options that are less toxic and highly targeted to patients suffering from breast, gastric, and other solid tumors."

Dr. Lu has spent her career focused on managing the treatment of women with breast cancer. Prior to her role at Ambrx, Dr. Lu was a Clinical Professor of Medicine and Medical Director of the Breast Oncology Program at the Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center. Prior to her role at USC, Dr. Lu was an Associate Professor of Clinical Medicine in the Division of Hematology and Oncology at the University of California, Los Angeles. Dr. Lu, a board certified medical oncologist, began her career at SUNY Stony Brook where she served as the Director of Breast Medical Oncology for several years.

Dr. Lu received a M.D. from Peking University School of Medicine as well as a Ph.D. from Syracuse University focusing on epigenetics under the mentorship of Dr. David Allis (Rockefeller University). Dr. Lu completed her Hematology and Oncology Fellowship at New York University School of Medicine.

On May 17, 2022 Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, reported that Management will participate in the upcoming investor events set out below (Press release, Transgene, MAY 17, 2022, View Source [SID1234614757]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– UBS Global Healthcare Conference
May 23-25, 2022
New York City, NY, USA

– Spring European MidCap Event
June 23-24, 2022
Paris, France

– Conference Portzamparc
June 29, 2022
Paris, France

On May 17, 2022 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, reported that company management will participate in a fireside chat and one-on-one meetings in-person at the H.C. Wainwright Global Investment Conference, which is taking place in Miami, Florida from May 23 – 26, 2022 (Press release, Cardiff Oncology, MAY 17, 2022, View Source [SID1234614756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the fireside chat can be found below.

A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion.

On May 17, 2022 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported that it will present preclinical data at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2022 Annual Meeting highlighting the use of anti-c-kit CAR-T cells as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants (Press release, Poseida Therapeutics, MAY 17, 2022, View Source [SID1234614755]). The ASGCT (Free ASGCT Whitepaper) Annual Meeting is being held in Washington, D.C. and virtually May 16-19, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present preclinical data from our anti-c-kit CAR-T program demonstrating the broad capabilities of our platform technologies to potentially improve patient outcomes," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics. "P-ckit-ALLO1 is an allogeneic or ‘off-the-shelf’ adoptive cell therapy comprised of early memory T cells expressing key bone marrow homing markers that enable it to effectively eliminate hematopoietic stem cells (HSC) and robustly inhibit growth of acute myeloid leukemia (AML) cells in animal models. The data presented today show that P-ckit-ALLO1 could be an ideal treatment as both a safer HSC transplantation approach as well as an anti-tumor therapy."

Presentation details:

Poster Presentation: Anti-c-kit CAR-T Cells Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant Conditioning
Session Title: Cell Therapies II
Session Date/Time: Tuesday, May 17, 2022, 5:30 – 6:30 PM ET
Poster Board Number: Tu-239
Location: Walter E. Washington Convention Center, Hall D
Abstract Number: 734

P-ckit-ALLO1 leverages the Company’s proprietary piggyBac Gene Delivery System, Cas-CLOVER Site-specific Gene Editing System, and a proprietary "Booster Molecule" to develop fully allogeneic CAR-T cells targeting human c-kit, which is highly expressed on HSCs as well as on myeloid malignancies such as AML, meaning the treatment can be used for either HSC transplant conditioning or as a treatment for AML. In addition to the CAR gene, the piggyBac transposon includes a selection marker for generation of a pure CAR+ product and a proprietary fast-acting safety switch enabling rapid clearance of the reactive CAR-T cells prior to donor HSC transplant.

Data demonstrated that P-ckit-ALLO1 was able to eliminate 95% of HSCs in bone marrow within four days, which was sufficient to enable HSC transplant in a humanized mouse model with reduced acute myelotoxicity compared to busulfan. In addition, data demonstrated that P-ckit-ALLO1 was able to significantly inhibit growth of AML cells in animal models and significantly prolong survival. These encouraging data support the potential of anti-c-kit CAR-T cells for use as an alternative and less toxic conditioning regimen to facilitate HSC transplantation as well as a potential anti-tumor therapy.

On May 17, 2022 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference (Press release, Merus, MAY 17, 2022, https://ir.merus.nl/news-releases/news-release-details/merus-present-hc-wainwright-global-investment-conference [SID1234614754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.